KLK3 and neoplasm: We also assessed that adverse clinical tumor stage (cT2/3) was independently and inversely associated with PSA ≤ 20 ng/mL (OR = 0.398; 95% CI 0.185–0.858; p = 0.019) and younger age (age < 70 years); consequently, younger patients were less likely to have palpable tumors and PSA > 20 ng/mL (data not shown in Table 4).